Edwards Lifesciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.11-13 02:06

Edwards Lifesciences (NYSE:EW) Third Quarter 2024 ResultsKey Financial Results Revenue: US$1.35b (up 8.9% from 3Q 2023). Net income: US$363.5m (up 8.2% from 3Q 2023). Profit margin: 27% (in line with ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483936880?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","is_english":true,"pubTime":"2024-11-13 02:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2483936880","market":"sg","top_or_hot":-1,"title":"Edwards Lifesciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag","media":"Simply Wall St.","content":"<div>\n<p>Edwards Lifesciences (NYSE:EW) Third Quarter 2024 ResultsKey Financial Results Revenue: US$1.35b (up 8.9% from 3Q 2023). Net income: US$363.5m (up 8.2% from 3Q 2023). Profit margin: 27% (in line with ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-ew/edwards-lifesciences/news/edwards-lifesciences-third-quarter-2024-earnings-eps-beats-e\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Edwards Lifesciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEdwards Lifesciences Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-13 02:06 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-ew/edwards-lifesciences/news/edwards-lifesciences-third-quarter-2024-earnings-eps-beats-e><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Edwards Lifesciences (NYSE:EW) Third Quarter 2024 ResultsKey Financial Results Revenue: US$1.35b (up 8.9% from 3Q 2023). Net income: US$363.5m (up 8.2% from 3Q 2023). Profit margin: 27% (in line with ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-ew/edwards-lifesciences/news/edwards-lifesciences-third-quarter-2024-earnings-eps-beats-e\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EW","symbol_name":"爱德华兹","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-ew/edwards-lifesciences/news/edwards-lifesciences-third-quarter-2024-earnings-eps-beats-e","article_id":"2483936880","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483936880","pubTimestamp":1731434803,"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Edwards Lifesciences ( NYSE:EW ) Third Quarter 2024 Results Key Financial Results Revenue: US$1.35b (up 8.9% from 3Q...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"EW":"爱德华兹"},"translate_title":"爱德华兹生命科学2024年第三季度收益：每股收益超出预期，收入滞后","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EW":1},"content_text":"Edwards Lifesciences (NYSE:EW) Third Quarter 2024 ResultsKey Financial Results Revenue: US$1.35b (up 8.9% from 3Q 2023). Net income: US$363.5m (up 8.2% from 3Q 2023). Profit margin: 27% (in line with 3Q 2023). EPS: US$0.61 (up from US$0.55 in 3Q 2023).  NYSE:EW Earnings and Revenue Growth November 12th 2024 All figures shown in the chart above are for the trailing 12 month (TTM) period Edwards Lifesciences EPS Beats Expectations, Revenues Fall Short  Revenue missed analyst estimates by 1.0%.  Earnings per share (EPS) exceeded analyst estimates significantly.      Looking ahead, revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US.    Performance of the American Medical Equipment industry.  The company's share price is broadly unchanged from a week ago.   Balance Sheet Analysis While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet.  We've done some analysis and you can see our take on Edwards Lifesciences' balance sheet. Valuation is complex, but we're here to simplify it.Discover if Edwards Lifesciences might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483936880"}